Everolimus for Children With Recurrent or Progressive Low-Grade Glioma: Results From the Phase II PNOC001 Trial.
Daphne A Haas-KoganMariam S AboianJane E MinturnSarah E S LearyMohamed S AbdelbakiStewart GoldmanJennifer D ElsterAdam A KrayaMatthew R LuederDivya RamakrishnanMarc von ReppertKevin X LiuJo Lynne RokitaAdam C ResnickDavid A SolomonJoanna J PhillipsMichael D PradosAnnette M MolinaroSebastian M WaszakRomain MuellerPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2023)
fusion breakpoints may define biomarkers for progressive disease and should be assessed in future clinical trials.